Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
Prostate cancer (PCa) is the most frequently diagnosed cancer in Canadian men. While the
majority of PCa is slow growing and responds well to first line treatment, a proportion of
cases (10%) progress to metastatic form resulting in more than 4 000 deaths annually in
Canada and 250 000 worldwide. Currently, first line treatment for PCa includes surgery,
radiation and androgen deprivation therapy (ADT). A rapid evolution in the understanding of
disease biology, combined with approvals of new therapies including immunotherapy, novel
chemotherapy, hormonal agents and a bone calcium matrix-targeted radionuclide, along with
further drugs in development, have made treatment decisions for metastatic
castration-resistant prostate cancer (mCRPC) increasingly complex and challenging.
This is a Phase II Study of Cabazitaxel plus prednisone in patients with metastatic
castration-resistant prostate cancer (mCRPC). The current study is designed to determine if
cabazitaxel will improve progression free survival (PFS) or overall survival (OS).
This study will enroll patients with mCRPC, who have been previously treated and progressed
under docetaxel or abiraterone regimen.
Patients must meet the study eligibility criteria and must be competent to give informed
consent.